Gold: Clear Breakout Still Awaited

Spot gold saw swing trading in the last few sessions, amid conflicting news regarding a potential coronavirus vaccine development...

Gold 2

Spot gold saw swing trading in the last few sessions, amid conflicting news regarding a potential coronavirus vaccine development. On Monday, U.S. biotech firm Moderna announced positive results for a coronavirus vaccine trial. However a day later, health-oriented news agency STAT questioned the company's report, pointing out that it did not provide critical data and it would be impossible to draw a conclusion.

The precious metal briefly surpassed its high marked in April, though a follow-through is still yet to be seen. Yesterday, the latest Federal Reserve monetary meeting minutes reiterated the message that the Fed "was committed to using its full range of tools to support the U.S. economy". Meanwhile, Bloomberg data showed that total ETF holdings of gold rose for a 19th straight session on Wednesday, suggesting persistent investors' demand.


From a technical point of view, spot gold remains on the upside as shown on the 1-hour chart. Currently, it is trading within a bullish channel drawn from May 1, while staying above its previous trading range marked in the first half of this month. The level at $1,726 might be considered as the nearest support level, with prices likely to test the 1st and 2nd resistance at $1,765 and $1,776 respectively. Alternatively, a break below may signal a downturn and open a path to $1,711 and $1,691.

Source: TradingView, Gain Capital

More from Gold

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.